je.st
news
Tag: immunotherapy
Immunotherapy: Using our immune system to fight cancer
2017-12-29 01:38:09| BBC News | Business | UK Edition
Immunotherapy is a breakthrough technology that scientists hope will one day lead to cures for previously untreatable cancers.
Tags: system
fight
cancer
immune
Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
2016-04-12 23:00:22| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Mercks house dust mite sublingual allergy immunotherapy (SLIT) tablet. Language: English read more
Tags: house
application
license
acceptance
Accelerate Development Of Cancer Immunotherapy (iOnc) Drugs With New PathHunter Checkpoint Assays From DiscoveRx
2016-02-03 03:52:40| drugdiscoveryonline News Articles
DiscoveRx Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, announced today the expansion of its PathHunter cell-based assays portfolio with the release of PathHunter Checkpoint Assays
Tags: development
cancer
drugs
accelerate
Merck Announces Initial Results for KEYTRUDA (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
2015-11-21 22:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three studies investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with three other immunotherapies epacadostat, IMLYGICTM (talimogene laherparepvec), and ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestors:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
international
research
society
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
2015-11-03 12:58:00| Merck.com - Product News
Dateline City: LONDON & KENILWORTH, N.J. Phase I first-in-human study to evaluate GSKs OX40 agonist GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSKs investigational immunotherapy GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. Language: English Contact: MerckMedia Relations:Pamela Eisele, +1 267-305-3558orAn Phan, +1 908-255-6325orInvestor Relations:Justin Holko, +1 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
potential
treatment
combination